Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma

[1]  A. Olivi,et al.  Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis , 2022, Journal of personalized medicine.

[2]  M. Heinrich,et al.  Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor , 2021, Frontiers in Oncology.

[3]  C. Scapoli,et al.  A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib. , 2020, Neuro-oncology.

[4]  A. Brandes,et al.  Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis , 2020, Clinical Cancer Research.

[5]  Hong Wu,et al.  Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway , 2020, Acta Pharmacologica Sinica.

[6]  M. Weller,et al.  How did lomustine become standard of care in recurrent glioblastoma? , 2020, Cancer treatment reviews.

[7]  A. Olivi,et al.  5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery. , 2020, Neurosurgery.

[8]  Zhongming Zhao,et al.  Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma , 2018, Neuro-oncology.

[9]  A. Brandes,et al.  Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. , 2019, The Lancet. Oncology.

[10]  Martin Klein,et al.  Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.

[11]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[12]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[13]  [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[14]  R. Bourgon,et al.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Dent,et al.  Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells , 2015, Journal of cellular physiology.

[16]  Matthias A. Karajannis,et al.  Glioblastoma multiforme: State of the art and future therapeutics , 2014, Surgical neurology international.

[17]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[18]  L. Ricci-Vitiani,et al.  Expression of EGFRvIII in glioblastoma: prognostic significance revisited. , 2011, Neoplasia.

[19]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[20]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Hornberg,et al.  Abstract B4: Regorafenib: a new oral multikinase inhibitor of angiogenic, stromal and oncogenic (receptor tyrosine) kinases with potent preclinical antitumor activity , 2009 .

[22]  Douglas S. Richardson,et al.  RET ligand-induced internalization and its consequences for downstream signaling , 2006, Oncogene.

[23]  H. Reber,et al.  The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. , 2005, Cancer research.

[24]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[25]  J. Sneep,et al.  With a summary , 1945 .